1
|
Alghonemy WY, Helal MB. Systemic immune response development in Albino rats after retrograde instillation of COVID-19 vaccine to submandibular salivary gland: An experimental study. J Oral Biol Craniofac Res 2022; 12:332-338. [PMID: 35341219 PMCID: PMC8938316 DOI: 10.1016/j.jobcr.2022.03.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 02/26/2022] [Accepted: 03/20/2022] [Indexed: 11/30/2022] Open
Abstract
Objective This study aimed to investigate whether using the submandibular gland duct (SMD) as an alternative mucosal route for vaccine administration induced anti-COVID-19 specific immunity. Material and methods Forty rats were randomized equally into four groups; Group I: Rats did not receive any intervention. Group II: Rats were subjected to intramuscular (IM) injection of COVID-19 vaccine. Group III: Rats were subjected to ductal cannulation by retrograde instillation of sterile saline into right SMD. Group IV: Rats in this group who had 0.5 ml of COVID-19 vaccine retrogradely injected into the right SMD. Subsequently, rats were examined for anti-COVID-19 specific antibodies (IgG). Also, light microscopic observation of glandular changes and immunohistochemical staining for CD20 was performed. Results The obtained results demonstrated a significant increase in anti-COVID-19 IgG levels in all rats vaccinated via intraductal immunization (group IV) compared to group II. Histologically, ectopic follicles were found within the glandular lobules of the inoculated submandibular gland (SMG) in group IV. In addition, the nearby lymph node in group IV demonstrated reactive follicle characteristics in the form of activated secondary follicles with germinal centers (GCs). Immunohistochemically, CD20 was localized in group IV in GCs of the ectopic lymphoid tissue and the nearby lymph nodes while group I, group II, and III demonstrated negative immunoreactivity. Conclusion The immune response demonstrated by intraductal SG immunization is generally more significant than that elicited by IM inoculation of the same vaccine. Salivary gland intraductal vaccination developed a systemic immune response. High antibody levels are obtained via salivary glands intraductal vaccination. Salivary glands are a potential mucosal route for administering vaccines.
Collapse
Affiliation(s)
- Wafaa Yahia Alghonemy
- Corresponding author. Faculty of Dentistry, Tanta University, Faculty of Dentistry, El-Giesh St, Tanta, Gharbia, Egypt.
| | | |
Collapse
|
2
|
El Helou G, Ponzio TA, Goodman JF, Blevins M, Caudell DL, Raviprakash KS, Ewing D, Williams M, Porter KR, Sanders JW. Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands. TROPICAL DISEASES TRAVEL MEDICINE AND VACCINES 2020; 6:10. [PMID: 32518668 PMCID: PMC7268334 DOI: 10.1186/s40794-020-00111-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/15/2020] [Accepted: 05/25/2020] [Indexed: 11/10/2022]
Abstract
Introduction and background A tetravalent DNA vaccine for Dengue virus is under development but has not yet achieved optimal immunogenicity. Salivary glands vaccination has been reported efficacious in rodents and dogs. We report on a pilot study testing the salivary gland as a platform for a Dengue DNA vaccine in a non-human primate model. Materials and methods Four cynomolgus macaques were used in this study. Each macaque was pre-medicated with atropine and sedated with ketamine. Stensen’s duct papilla was cannulated with a P10 polyethylene tube, linked to a 500ul syringe. On the first two infusions, all macaques were infused with 300ul of TVDV mixed with 2 mg of zinc. For the 3rd infusion, to increase transfection into salivary tissue, two animals received 100uL TVDV mixed with 400uL polyethylenimine 1μg/ml (PEI) and the other two animals received 500uL TVDV with zinc. Antibody titers were assessed 4 weeks following the second and third infusion. Results and conclusions SGRI through Stensen’s duct is a well-tolerated, simple and easy to reproduce procedure. TVDV infused into macaques salivary glands elicited a significantly weaker antibody response than with different delivery methods.
Collapse
Affiliation(s)
- Guy El Helou
- Department of Medicine, Division of Infectious Diseases and Global Medicine, University of Florida, Gainesville, FL USA
| | - Todd A Ponzio
- Department of Medicine, Division of Infectious Diseases, Wake Forest School of Medicine, Winston-Salem, NC USA
| | - Joseph F Goodman
- Department of Otolaryngology, George Washington School of Medicine and Health Sciences, Washington, DC 20037 USA
| | - Maria Blevins
- Department of Medicine, Division of Infectious Diseases, Wake Forest School of Medicine, Winston-Salem, NC USA
| | - David L Caudell
- Department of Pathology, Section on Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC USA
| | | | - Daniel Ewing
- Naval Medical Research Center, Silver Spring, MD USA
| | - Maya Williams
- Naval Medical Research Center, Silver Spring, MD USA
| | | | - John W Sanders
- Department of Medicine, Division of Infectious Diseases, Wake Forest School of Medicine, Winston-Salem, NC USA
| |
Collapse
|
3
|
Ponzio TA, Sanders JW. The salivary gland as a target for enhancing immunization response. TROPICAL DISEASES TRAVEL MEDICINE AND VACCINES 2017; 3:4. [PMID: 28883974 PMCID: PMC5531011 DOI: 10.1186/s40794-017-0047-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Accepted: 02/13/2017] [Indexed: 12/02/2022]
Abstract
Background An organism’s immune response to a vaccine is dependent on a number of factors, including the site of immunization. While muscle is the most common site for vaccine administration, other sites, including the salivary gland, are poised to confer stronger and broader immunoprotection. Findings Studies exploring the salivary gland as an immunization site have involved protein antigens, as well as live pathogens and DNA vaccines. While intraductal instillation of protein antigens into the salivary gland may result in a relatively transient increase in antibody production, DNA or attenuated pathogen vaccination appear to confer a lasting widespread mucosal immune response that includes robust salivary and enteric IgA, as well as high levels of circulating IgG. Furthermore, vaginal and lung antibodies are also seen. For enteric pathogens, a common class of pathogen encountered by travelers, this type of immune response provides for a level of redundant protection against foreign microbes with mucosal targets. Conclusion The strength of immune response conferred by salivary gland vaccination is generally stronger than that seen in response to the same vaccine at a comparison site. For example, where other routes fail, immunization of the salivary gland has been shown to confer protection in lethal challenge models of infectious pathogens. A host of vaccines currently under development suffer from immunogenicity challenges, adding to the widespread interest and search for novel routes and adjuvants. With its capability to facilitate a strong and broad immune response, the salivary gland warrants consideration as an immunization site, especially for vaccines with immunogenicity challenges, as well as vaccines that would benefit from combined systemic and mucosal immunity.
Collapse
Affiliation(s)
- Todd A Ponzio
- Naval Medical Research Center, 503 Robert Grant Ave., Silver Spring, MD 20910 USA.,Wake Forest University School of Medicine, Winston-Salem, USA
| | - John W Sanders
- Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157 USA.,Hefner Veterans Affairs Medical Center, Salisbury, NC UK
| |
Collapse
|
4
|
Abstract
Human Immunodeficiency Virus (HIV) transmission through genital and rectal mucosa has led to intensive study of mucosal immune responses to HIV and to the development of a vaccine administered locally. However, HIV transmission through the oral mucosa is a rare event. The oral mucosa represents a physical barrier and contains immunological elements to prevent the invasion of pathogenic organisms. This particular defense differs between micro-compartments represented by the salivary glands, oral mucosa, and palatine tonsils. Secretory immunity of the salivary glands, unique features of cellular structure in the oral mucosa and palatine tonsils, the high rate of oral blood flow, and innate factors in saliva may all contribute to the resistance to HIV/Simian Immunodeficiency Virus (SIV) oral mucosal infection. In the early stage of HIV infection, humoral and cellular immunity and innate immune functions in oral mucosa are maintained. However, these particular immune responses may all be impaired as a result of chronic HIV infection. A better understanding of oral mucosal immune mechanisms should lead to improved prevention of viral and bacterial infections, particularly in immunocompromised persons with Acquired Immune Deficiency Syndrome (AIDS), and to the development of a novel strategy for a mucosal AIDS vaccine, as well as vaccines to combat other oral diseases, such as dental caries and periodontal diseases.
Collapse
Affiliation(s)
- F X Lü
- California National Primate Research Center and Center for Comparative Medicine, University of California Davis, Davis, CA 95616, USA.
| | | |
Collapse
|
5
|
|
6
|
Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv 2011; 7:1433-46. [PMID: 21118032 DOI: 10.1517/17425247.2010.538047] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
IMPORTANCE OF THE FIELD Many vaccines require the use of an adjuvant to achieve immunity. So far, few adjuvants have advanced successfully through clinical trials to become part of licensed vaccines. Vaxfectin® (Vical, CA, USA) represents a next-generation adjuvant with promise as a platform technology, showing utility with both plasmid DNA (pDNA) and protein-based vaccines. AREAS COVERED IN THIS REVIEW This review describes the chemical, physical, preclinical and clinical development of Vaxfectin for pDNA-based vaccines. Also included is the preclinical development of Vaxfectin-adjuvanted protein- and peptide-based vaccines. WHAT THE READER WILL GAIN The reader will gain knowledge of vaccine adjuvant development from bench to bedside. TAKE HOME MESSAGE Vaxfectin has effectively boosted the immune response against a range of pDNA-expressed pathogenic antigens in preclinical models extending from rodents to non-human primates. In the clinic, Vaxfectin-adjuvanted pDNA-based H5N1 influenza vaccines have been shown to be well tolerated and to result in durable immune responses within the predicted protective range reported for protein-based vaccines.
Collapse
Affiliation(s)
- Sean M Sullivan
- Vical, Inc., Pharmaceutical Sciences, 10390 Pacific Center Court, San Diego, CA 92121, USA.
| | | | | | | | | |
Collapse
|
7
|
Grewal JS, Pilgrim MJ, Grewal S, Kasman L, Werner P, Bruorton ME, London SD, London L. Salivary glands act as mucosal inductive sites via the formation of ectopic germinal centers after site-restricted MCMV infection. FASEB J 2011; 25:1680-96. [PMID: 21307334 DOI: 10.1096/fj.10-174656] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
We investigated the hypothesis that salivary gland inoculation stimulates formation of ectopic germinal centers (GCs), transforming the gland into a mucosal inductive site. Intraglandular infection of mice with murine cytomegalovirus (MCMV; control: UV-inactivated MCMV) induces salivary gland ectopic follicles comprising cognate interactions between CD4(+) and B220(+) lymphocytes, IgM(+) and isotype-switched IgG(+) and IgA(+) B cells, antigen presenting cells, and follicular dendritic cells. B cells coexpressed the GC markers GCT (57%) and GL7 (52%), and bound the lectin peanut agglutinin. Lymphoid follicles were characterized by a 2- to 3-fold increase in mRNA for CXCL13 (lymphoid neogenesis), syndecan-1 (plasma cells), Blimp-1 (plasma cell development/differentiation), and a 2- to 6-fold increase for activation-induced cytidine deaminase, PAX5, and the nonexcised rearranged DNA of an IgA class-switch event, supporting somatic hypermutation and class-switch recombination within the salivary follicles. Intraglandular inoculation also provided protection against a systemic MCMV challenge, as evidenced by decreased viral titers (10(5) plaque-forming units to undetectable), and restoration of normal salivary flow rates from a 6-fold decrease. Therefore, these features suggest that the salivary gland participates in oral mucosal immunity via generation of ectopic GCs, which function as ectopic mucosal inductive sites.
Collapse
Affiliation(s)
- Jasvir S Grewal
- Department of Oral Biology and Pathology, School of Dental Medicine, Stony Brook University, Stony Brook, New York 11794, USA
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Hartikka J, Geall A, Bozoukova V, Kurniadi D, Rusalov D, Enas J, Yi JH, Nanci A, Rolland A. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med 2008; 10:770-82. [PMID: 18425981 DOI: 10.1002/jgm.1199] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Plasmid DNA (pDNA) vaccines have generated significant interest for the prevention or treatment of infectious diseases. Broader applications may benefit from the identification of safe and potent vaccine adjuvants. This report describes the development of a novel polymer-based formulation to enhance the immunogenicity of pDNA-based vaccines. METHODS Plasmid DNA was formulated with a nonionic block copolymer, poloxamer CRL1005, and the cationic surfactant benzalkonium chloride (BAK) to produce a thermodynamically stable, self-assembling system. The influence of parameters such as polymer concentration and BAK composition on the immune responses was evaluated in mice vaccinated with pDNA encoding influenza nucleoprotein. RESULTS At concentrations of 7.5 mg/ml CRL1005, 0.3 mM BAK and 5 mg/ml pDNA, CRL1005/BAK/pDNA particles had a mean diameter of 261 +/- 0.2 nm and a surface charge of - 11.6 +/- 0.9 mV. The negative surface charge and atomic force microscopy images suggested that pDNA binds to BAK adsorbed to the surface of poloxamer particles. The CRL1005/BAK/pDNA formulation significantly enhanced antigen-specific cellular and humoral immune responses, and increased transgene levels in muscle and serum. The complexity of the formulation was reduced by replacing the commercial BAK, which is a mixture of four alkyl chains, with a C14 BAK homolog. The substitution yielded an analytically preferable formulation with equivalent physical characteristics and immunogenicity. CONCLUSIONS The results suggest that the CRL1005/BAK/pDNA formulation may enhance immunogenicity by improving the delivery of pDNA-based vaccines. This formulation is currently being evaluated for the prevention of CMV-associated disease in a phase 2 clinical trial.
Collapse
Affiliation(s)
- Jukka Hartikka
- Vical Incorporated, 10390 Pacific Center Court, San Diego, CA 92121-4340, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Sedegah M, Rogers WO, Belmonte A, Belmonte M, Banania G, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, Doolan DL. Vaxfectin™ enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006; 24:1921-7. [PMID: 16298024 DOI: 10.1016/j.vaccine.2005.10.041] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2005] [Revised: 10/14/2005] [Accepted: 10/21/2005] [Indexed: 10/25/2022]
Abstract
We evaluated the capacity of the cationic lipid based formulation, Vaxfectin, to enhance the immunogenicity and protective efficacy of DNA-based vaccine regimens in the Plasmodium yoelii murine malaria model. We immunized Balb/c mice with varying doses (0.4-50 microg) of plasmid DNA (pDNA) encoding the P. yoelii circumsporozoite protein (PyCSP), either in a homologous DNA/DNA regimen (D-D) or a heterologous prime-boost DNA-poxvirus regimen (D-V). At the lowest pDNA doses, Vaxfectin substantially enhanced IFA titers, ELISPOT frequencies, and protective efficacy. Clinical trials of pDNA vaccines have often used low pDNA doses based on a per kilogram weight basis. Formulation of pDNA vaccines in Vaxfectin may improve their potency in human clinical trials.
Collapse
Affiliation(s)
- Martha Sedegah
- Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
DNA Vaccines for Mucosal Immunity to Infectious Diseases. Mucosal Immunol 2005. [DOI: 10.1016/b978-012491543-5/50064-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
11
|
Manthorpe M, Hobart P, Hermanson G, Ferrari M, Geall A, Goff B, Rolland A. Plasmid vaccines and therapeutics: from design to applications. ADVANCES IN BIOCHEMICAL ENGINEERING/BIOTECHNOLOGY 2005; 99:41-92. [PMID: 16568888 DOI: 10.1007/10_003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
In the late 1980s, Vical and collaborators discovered that the injection into tissues of unformulated plasmid encoding various proteins resulted in the uptake of the plasmid by cells and expression of the encoded proteins. After this discovery, a period of technological improvements in plasmid delivery and expression and in pharmaceutical and manufacturing development was quickly followed by a plethora of human clinical trials testing the ability of injected plasmid to provide therapeutic benefits. In this chapter, we summarize in detail the technologies used in the most recent company-sponsored clinical trials and discuss the potential for future improvements in plasmid design, manufacturing, delivery, formulation and administration. A generic path for the clinical development of plasmid-based products is outlined and then exemplified using a case study on the development of a plasmid vaccine from concept to clinical trial.
Collapse
|
12
|
Affiliation(s)
- R Zufferey
- The Institute of Neurosciences, Swiss Federal Institute of Technology Lausanne, EPFL.
| | | |
Collapse
|
13
|
Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC. Salivary gland genetic vaccination: a scalable technology for promoting distal mucosal immunity and heightened systemic immune responses. Vaccine 2004; 22:2500-4. [PMID: 15193415 DOI: 10.1016/j.vaccine.2003.12.034] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2003] [Accepted: 12/01/2003] [Indexed: 10/26/2022]
Abstract
Use of plasmid DNA for vaccination has been demonstrated quite successfully in small rodents. However, some of the many challenges of DNA vaccine development are the relatively low performance obtained in larger animals and a generally weak mucosal immune response. Vaccination through salivary gland (SG) cannulation and delivery of aqueous solutions of DNA is one potential solution. The scalability of SG DNA vaccination was tested in multiple animal models; antigen specific titers above 10,000 were demonstrated in dogs and rats. Immune responses were also present at a variety of mucosal sites. In conclusion, our data demonstrate that DNA vaccination to the SG presents a unique and advantageous method for eliciting systemic and mucosal immune responses.
Collapse
Affiliation(s)
- Sean N Tucker
- Genteric Inc. 1650, Harbor Bay Parkway, Alameda, CA 94502, USA.
| | | | | | | | | | | |
Collapse
|
14
|
Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC. Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Mol Ther 2003; 8:392-9. [PMID: 12946312 DOI: 10.1016/s1525-0016(03)00180-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Gene transfer to salivary glands by retrograde perfusion of the salivary duct has been shown to result in production of the encoded protein. We sought to determine if this technique would be useful for genetic immunization. In studies that compare delivery of DNA to either the salivary gland (SG) or muscle (im), mean plasma IgG and IgA titers obtained following SG delivery were 46- and 86-fold greater, respectively, than those following im delivery. We also tested the hypothesis that SG vaccination could generate mucosal responses in sites proximal and distal to DNA administration. SG-treated animals produced specific antibodies within saliva, vaginal fluid, and lung washes as well as demonstrating robust specific responses in Peyer's patches. In a test of functional immunity, animals vaccinated with DNA by SG retrograde perfusion were significantly more resistant to the effects of lethal anthrax challenge than im DNA-vaccinated animals. These data suggest that SG genetic immunization may offer advantages over conventional routes of vaccination.
Collapse
Affiliation(s)
- Sean N Tucker
- Genteric, Inc., 1650 Harbor Bay Parkway, Alameda, California 94502, USA.
| | | | | | | | | | | |
Collapse
|